Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
08:03pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
07:05pm, Wednesday, 18'th May 2022 Zacks Investment Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
07:00pm, Thursday, 12'th May 2022 Benzinga
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc
Where Vir Biotechnology Stands With Analysts
01:27pm, Friday, 06'th May 2022 Benzinga
Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
0
1
0
0
Las
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates
09:25pm, Thursday, 05'th May 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates
06:48pm, Thursday, 05'th May 2022
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
07:19pm, Wednesday, 04'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
04:33pm, Wednesday, 04'th May 2022
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
These stocks soared during the pandemic, and then crashed. Ten are now expected to double in price.
11:00am, Wednesday, 04'th May 2022 MarketWatch
The group rose at least 300% in the pandemic before crashing 70% or more.
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
05:26pm, Monday, 02'nd May 2022 Benzinga
Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:
Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected
03:42pm, Monday, 02'nd May 2022
Vir Biotechnology had obtained about $917.2 million of sotrovimab collaboration revenue in 2021; Expects about $1.1 billion in revenues with all doses delivered by 1st half of 2022. About 95% of patie
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
01:41pm, Monday, 02'nd May 2022
Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
03:10pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
